Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$212.15 USD

212.15
651,165

+1.37 (0.65%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $211.69 -0.46 (-0.22%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Dental Supplies

Zacks News

BioScrip's Infusion Business Strong, Dull 2017 View a Drag (Revised)

BioScrip's (BIOS) progressive CORE plan should enhance its financial position. However, the company's 2017 outlook loses steam based on an anticipated adverse impact of Cures Act legislation.

    Align Technology-Patterson Dental Deal Expands iTero Reach

    Align Technology (ALGN) progresses with a slew of developments in the scanners and services segment.

      Align Technology's Invisalign Sales Strong Amid Margin Woes

      Align Technology's (ALGN) huge InvisAlign prospects in North America and international regions render optimism. However, escalating costs and expenses put pressure on the company's margins.

        Cerner (CERN) Banks on RCM & PH Platforms, Competition Rife

        Cerner's (CERN) growth in order bookings would continue to boost growth prospects. However, steep competition in the HCIT space raise concern.

          Quality Systems Professional Service a Drag, Competition Rife

          Quality Systems' (QSII) performance in the professional service business continues to be a drag in recent times. Also, macro headwinds continue to put pressure on performance.

            Here's Why You Must Add Chemed (CHE) Stock to Your Portfolio

            Chemed Corporation's (CHE) promising Roto-Rooter revenue outlook as well as an increased bottom-line guidance bode well of the company's future.

              BioScrip's Infusion Business Strong, Dull 2017 View a Drag

              BioScrip's (BIOS) progressive CORE plan should enhance its financial position. However, the company's 2017 outlook loses steam based on an anticipated adverse impact of Cures Act legislation.

                Stryker (SYK) to Gain From Solid Portfolio and Acquisitions

                Stryker's (SYK) diverse product portfolio alongside acquisition-driven strategy would continue to boost growth prospects. However, competition in the Chinese market raise concern.

                  Zimmer (ZBH) Plagued by Various Internal and External Issues

                  Zimmer Biomet (ZBH) continues to suffer a bad patch, entangled with issues including its decade-old CEO's recent exit post a dull earnings season due to poor knee business.

                    Myriad Genetics' EndoPredict Gets Positive Coverage Decision

                    Considering Myriad Genetics' (MYGN) EndoPredict has been used clinically in more than 15,000 patients, we are confident about the growing adaptability of this test post the Medicare coverage approval.

                      Walgreens Boots to Gain From Altered Rite Aid Deal, Alliance

                      The new acquisition deal with Rite Aid would enable Walgreens (WBA) to buy nearly half of its business at a deal value, almost one-third of the original price. Downsides remain a challenge.

                        Fluidigm (FLDM) Licenses CFTR Assay From Baylor Genetics

                        Fluidigm (FLDM) has licensed rights to commercialize the cystic fibrosis transmembrane conductance regulator. The company is focused on improving its Juno automated microfluidic system.

                          Allscripts, Elligo Health Enter in Strategic Partnership

                          Allscripts' (MDRX) Strategic Partnership with Elligo Health would aid the company in capturing the Clinical Research Organizations' lucrative market.

                            Walgreens' (WBA) Research Website to Add Value in Healthcare

                            Walgreens Boots Alliance's (WBA) Center for Health & Wellbeing Research is set to improve patient care and outcomes while reducing health care costs at the same time.

                              Omnicell Upgrades Web Portal, Grows in Medication Management

                              Omnicell (OMCL) makes progress in medicare adherence with four new enhancements to its web portal PMAP.

                                Henry Schein to Offer CAEK's HIPAA Software LayerCompliance

                                Henry Schein (HSIC) inks an agreement to distribute CAEK's HIPAA related software, LayerCompliance.

                                  Here's Why Investors Should Buy Edwards Lifesciences Now

                                  Market is upbeat about Edwards Lifesciences's (EW) recent FDA approvals and strong 2017 guidance.

                                    Here's Why Investors Should Buy Align Technology (ALGN) Now

                                    Align Technology (ALGN) continues to ride high on robust growth in the Invisalign space.

                                      Intuitive Surgical at 52-Week High: What's Driving the Stock?

                                      Share price of Intuitive Surgical (ISRG) reaches a new 52-week high on the back of its new partnership and impressive second-quarter performance.

                                        Medtronic Announces RESOLUTE ONYX ONE-MONTH DAPT Study

                                        Medtronic (MDT) announces a clinical trial to evaluate one-month dual antiplatelet therapy in patients implanted with the Resolute Onyx Drug-Eluting Stent during PCI procedures.

                                          Haemonetics Plasma Arm Grows Strong, Blood Center Sluggish

                                          Haemonetics (HAE) registers strong top-line growth, banking on Plasma, TEG, hemostasis management as well as a strong cash position. Blood Center drag continues.

                                            Varian (VAR) Rides on Oncology and Proton Therapy Businesses

                                            Varian Medical's (VAR) oncology and Proton therapy business' growth prospects remain impressive. However, competition in the radiotherapy space raise concern.

                                              Civitas Solutions (CIVI) Q3 Earnings Beat, Revenues Miss

                                              Civitas Solutions (CIVI) gains on strength in Post-Acute Specialty Rehabilitation Services and Adult Day Health services in Q3. However, tweaked full-year 2017 guidance signals dull prospects.

                                                Myriad Genetics (MYGN) Grows on Higher Cancer Test Volumes

                                                Myriad Genetics (MYGN) rides high on strength in Molecular Diagnostics with significant contributions from GeneSight. Also, hereditary cancer testing continues to witness sequential growth.

                                                  STERIS (STE) Banks on Organic Growth, Competition Intense

                                                  STERIS' (STE) cost structure is likely to be enhanced through recent organizational changes.